Nektar Therapeutics annual revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Nektar Therapeutics Revenue Growth & History (NKTR)
Nektar Therapeutics reported $55.2M in revenue for fiscal 2025, a decrease of 43.89% from the previous fiscal year.
View full Nektar Therapeutics company overviewNektar Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $55.2M | −$43.2M | −43.89% |
| 2024 | 2024-12-31 | $98.4M | $8.3M | +9.22% |
| 2023 | 2023-12-31 | $90.1M | −$1.9M | −2.10% |
| 2022 | 2022-12-31 | $92.1M | −$9.9M | −9.67% |
| 2021 | 2021-12-31 | $101.9M | −$51.0M | −33.36% |
| 2020 | 2020-12-31 | $152.9M | $38.3M | +33.41% |
| 2019 | 2019-12-31 | $114.6M | −$1.08B | −90.40% |
| 2018 | 2018-12-31 | $1.19B | $885.6M | +287.81% |
| 2017 | 2017-12-31 | $307.7M | $142.3M | +86.00% |
| 2016 | 2016-12-31 | $165.4M | −$65.3M | −28.32% |
| 2015 | 2015-12-31 | $230.8M | $30.1M | +14.99% |
| 2014 | 2014-12-31 | $200.7M | $51.8M | +34.77% |
| 2013 | 2013-12-31 | $148.9M | $67.7M | +83.42% |
| 2012 | 2012-12-31 | $81.2M | $9.7M | +13.59% |
| 2011 | 2011-12-31 | $71.5M | −$87.6M | −55.06% |
| 2010 | 2010-12-31 | $159.0M | $87.1M | +121.10% |
| 2009 | 2009-12-31 | $71.9M | — | — |
Nektar Therapeutics quarterly revenue
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.1M | −$1.0M | −9.34% |
| Q1 2026 | 2026-03-31 | $10.9M | $401,000 | +3.83% |
| Q4 2025 | 2025-12-31 | $21.8M | −$7.4M | −25.25% |
| Q3 2025 | 2025-09-30 | $11.8M | −$12.3M | −51.13% |
| Q2 2025 | 2025-06-30 | $11.2M | −$12.3M | −52.42% |
| Q1 2025 | 2025-03-31 | $10.5M | −$11.2M | −51.66% |
| Q4 2024 | 2024-12-31 | $29.2M | $5.3M | +22.15% |
| Q3 2024 | 2024-09-30 | $24.1M | −$20,000 | −0.08% |
| Q2 2024 | 2024-06-30 | $23.5M | $3.0M | +14.59% |
| Q1 2024 | 2024-03-31 | $21.6M | $45,000 | +0.21% |
| Q4 2023 | 2023-12-31 | $23.9M | $1.9M | +8.45% |
| Q3 2023 | 2023-09-30 | $24.1M | $519,000 | +2.20% |
| Q2 2023 | 2023-06-30 | $20.5M | −$1.1M | −5.03% |
| Q1 2023 | 2023-03-31 | $21.6M | −$3.2M | −13.00% |
| Q4 2022 | 2022-12-31 | $22.0M | −$3.0M | −11.94% |
| Q3 2022 | 2022-09-30 | $23.6M | −$1.3M | −5.20% |
| Q2 2022 | 2022-06-30 | $21.6M | −$6.7M | −23.81% |
| Q1 2022 | 2022-03-31 | $24.8M | $1.2M | +4.97% |
| Q4 2021 | 2021-12-31 | $25.0M | $1.5M | +6.59% |
| Q3 2021 | 2021-09-30 | $24.9M | −$5.1M | −17.02% |
| Q2 2021 | 2021-06-30 | $28.3M | −$20.5M | −42.00% |
| Q1 2021 | 2021-03-31 | $23.6M | −$26.9M | −53.24% |
| Q4 2020 | 2020-12-31 | $23.5M | −$10.4M | −30.71% |
| Q3 2020 | 2020-09-30 | $30.0M | $815,000 | +2.79% |
| Q2 2020 | 2020-06-30 | $48.8M | $25.5M | +109.51% |
| Q1 2020 | 2020-03-31 | $50.6M | $22.4M | +79.20% |
| Q4 2019 | 2019-12-31 | $33.9M | −$6.0M | −14.98% |
| Q3 2019 | 2019-09-30 | $29.2M | $1.5M | +5.24% |
| Q2 2019 | 2019-06-30 | $23.3M | −$1.06B | −97.86% |
| Q1 2019 | 2019-03-31 | $28.2M | −$9.8M | −25.77% |
| Q4 2018 | 2018-12-31 | $39.8M | −$55.6M | −58.28% |
| Q3 2018 | 2018-09-30 | $27.8M | −$125.2M | −81.85% |
| Q2 2018 | 2018-06-30 | $1.09B | $1.05B | +3044.69% |
| Q1 2018 | 2018-03-31 | $38.0M | $13.3M | +53.74% |
| Q4 2017 | 2017-12-31 | $95.5M | $58.0M | +154.92% |
| Q3 2017 | 2017-09-30 | $152.9M | $116.6M | +320.87% |
| Q2 2017 | 2017-06-30 | $34.6M | $1.8M | +5.56% |
| Q1 2017 | 2017-03-31 | $24.7M | −$34.2M | −58.00% |
| Q4 2016 | 2016-12-31 | $37.5M | −$1.9M | −4.88% |
| Q3 2016 | 2016-09-30 | $36.3M | −$23.6M | −39.39% |
| Q2 2016 | 2016-06-30 | $32.8M | $10.1M | +44.60% |
| Q1 2016 | 2016-03-31 | $58.9M | −$49.9M | −45.88% |
| Q4 2015 | 2015-12-31 | $39.4M | $19.8M | +101.37% |
| Q3 2015 | 2015-09-30 | $60.0M | −$72.9M | −54.88% |
| Q2 2015 | 2015-06-30 | $22.7M | −$5.9M | −20.52% |
| Q1 2015 | 2015-03-31 | $108.8M | $89.0M | +450.31% |
| Q4 2014 | 2014-12-31 | $19.6M | −$11.6M | −37.23% |
| Q3 2014 | 2014-09-30 | $132.9M | $72.0M | +118.15% |
| Q2 2014 | 2014-06-30 | $28.5M | −$5.3M | −15.80% |
| Q1 2014 | 2014-03-31 | $19.8M | −$3.2M | −14.05% |
| Q4 2013 | 2013-12-31 | $31.1M | $10.0M | +47.29% |
| Q3 2013 | 2013-09-30 | $60.9M | $42.5M | +230.81% |
| Q2 2013 | 2013-06-30 | $33.9M | $10.2M | +42.97% |
| Q1 2013 | 2013-03-31 | $23.0M | $5.1M | +28.16% |
| Q4 2012 | 2012-12-31 | $21.1M | $5.4M | +33.99% |
| Q3 2012 | 2012-09-30 | $18.4M | −$8.7M | −31.98% |
| Q2 2012 | 2012-06-30 | $23.7M | $6.4M | +36.66% |
| Q1 2012 | 2012-03-31 | $17.9M | $6.7M | +58.85% |
| Q4 2011 | 2011-12-31 | $15.8M | −$29.5M | −65.17% |
| Q3 2011 | 2011-09-30 | $27.1M | −$10.9M | −28.63% |
| Q2 2011 | 2011-06-30 | $17.3M | −$25.2M | −59.28% |
| Q1 2011 | 2011-03-31 | $11.3M | −$21.9M | −66.00% |
| Q4 2010 | 2010-12-31 | $45.3M | — | — |
| Q3 2010 | 2010-09-30 | $37.9M | — | — |
| Q2 2010 | 2010-06-30 | $42.6M | — | — |
| Q1 2010 | 2010-03-31 | $33.2M | — | — |
Nektar Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue declined from $152.9M to $55.2M, a compound annual decline of 18.43%. Nektar Therapeutics's latest reported quarter, Q2 2026, generated $10.1M in revenue, a decrease of 9.34% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Nektar Therapeutics source filings ↗